Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
Roche CT-388 Obesity Drug Posts 22.5% Weight Loss
Original Article by Miranda Murray & Ludwig Burger | Reuters | 28 January 2026
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.